{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for phenyl root_names_name in Any Name (approximate match)
Status:
US Previously Marketed
Source:
ALVODINE PIMINODINE ESYLATE by WINTHROP
(1961)
Source URL:
First approved in 1960
Class (Stereo):
CHEMICAL (ACHIRAL)
Piminodine is an analog of pethidine. It was used in medicine for obstetric analgesia and in dental procedures briefly during the 1960s and 1970s, but has largely fallen out of clinical use. Piminodine produces analgesia, sedation and euphoria and has typical side effects associated with opioids, including potentially serious respiratory depression, which can be life-threatening. Piminodine was more potent than desipramine and protriptyline under similar conditions. Compared to meperidine, piminodine is more potent and gives smoother duration. Piminodine can be addictive. Piminodine is currently a Schedule II controlled substance in the United States.
Status:
US Previously Marketed
Source:
AKINETON by ABBVIE
(1961)
Source URL:
First approved in 1959
Source:
AKINETON by ABBVIE
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Conditions:
Biperiden, sold under the brandname Akineton was used as an adjunct in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic). Was also useful in the control of extrapyramidal disorders due to central nervous system drugs such as phenothiazines and other groups of psychotropics. Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance. Atropine-like side effects such as dry mouth; blurred vision; drowsiness; euphoria or disorientation; urinary retention; postural hypotension; constipation; agitation; disturbed behavior may been seen. Only limited pharmacokinetic studies of biperiden in humans are available.
Status:
US Previously Marketed
Source:
AKINETON by ABBVIE
(1961)
Source URL:
First approved in 1959
Source:
AKINETON by ABBVIE
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Conditions:
Biperiden, sold under the brandname Akineton was used as an adjunct in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic). Was also useful in the control of extrapyramidal disorders due to central nervous system drugs such as phenothiazines and other groups of psychotropics. Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance. Atropine-like side effects such as dry mouth; blurred vision; drowsiness; euphoria or disorientation; urinary retention; postural hypotension; constipation; agitation; disturbed behavior may been seen. Only limited pharmacokinetic studies of biperiden in humans are available.
Status:
US Previously Marketed
Source:
ISADOXOL by HARVEY
(1961)
Source URL:
First approved in 1959
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Oxyphenisatin is a stimulant laxative that has been used by mouth and as an enema. Oxyphenisatin was introduced as Lavema by Winthrop in US in 1959. Oxyphenisatin was used as a cleansing enema apart
from x-ray studies and prior to urinary, gastro-intestinal and
cholecystography x-ray examination. Oxyphenisatin was also used for preoperative preparation of the large intestine and colon. May be mixed with
barium for x-ray examination of the large intestine.
Oxyphenisatin may cause jaundice. Oxyphenisatin-induced liver damage usually occurs when the
drug has been taken for at least six months and usually two years. Oxyphenisatin was withdrawn in most countries in the early 1970s.
Status:
US Previously Marketed
First approved in 1959
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and was formerly used in the sympathomimetic treatment of parkinsonism. Histamine receptor H1 antagonist. Chlorphenoxamine is used to treat Allergic conditions, it is reported as an ingredient of Systral in Germany, Malta, Portugal, Thailand, Turkey.
Status:
US Previously Marketed
Source:
SUVREN by AYERST
(1961)
Source URL:
First approved in 1958
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
CAPTODIAME, also known as captodiamine, is a diphenylmethane derivative. It is a 5-HT2c receptor antagonist and agonist at sigma-1 and D3 dopamine receptors. It is an antihistamine which is used as a sedative and anxiolytic. CAPTODIAME is probably useful in preventing benzodiazepine withdrawal syndrome.
Status:
US Previously Marketed
Source:
Orabilex by Fougera
(1958)
Source URL:
First approved in 1958
Source:
Orabilex by Fougera
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
BUNAMIODYL is an cholecystographic agent which was used to aid the radiographic visualization of the gallbladder for detecting the presence of gallstones in cholelithiasis patients. It was withdrawn from the market due to nephropathy.
Status:
First approved in 1958
Class (Stereo):
CHEMICAL (MIXED)
Targets:
Valethamate bromide ( sold under many brand names such as Epidosin, Dilaton, Valosin, Valamate, Osdil etc), a quarternary ammonium agent, has been used in augmentation of labor. Valethamate has antimuscarinic action and blocks cholinergic receptors in the ganglia. This action along with the direct action on the smooth muscles of the cervix is thought to help cervical dilatation during labor. Since it is not selective, it exerts anticholinergic side effects such as tachycardia, flushing, cotton mouth and photophobia due to mydriasis. Common side effects are palpitations, increased heart rate, arrhythmia, excessive thirst, reduced bronchial secretions, dry mouth, Photophobia, dry skin, loss of accommodation, slow heart rate, flushing.
Status:
US Previously Marketed
Source:
COMBID ISOPROPAMIDE by SKF
(1961)
Source URL:
First approved in 1957
Source:
DARBID by GLAXOSMITHKLINE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Isopropamide is a quaternary ammonium antimuscarinic with peripheral effects similar to those of atropine. It has been used as an adjunct in the treatment of peptic ulcer disease, in the relief of gastro-intestinal and urinary tract disorders associated with smooth muscle spasm, in rhinitis, and the relief of symptoms of cold.
Status:
US Previously Marketed
Source:
GLUTETHIMIDE by LANNETT
(1977)
Source URL:
First approved in 1957
Source:
DORIDEN by SANOFI AVENTIS US
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Glutethimide is a GABA agonist that was introduced by Ciba in 1954 as a safe alternative to barbiturates to treat insomnia. Before long, however, it had become clear that glutethimide was just as likely to cause addiction and caused similarly severe withdrawal symptoms. Glutethimide was discontinued in the US by manufacturers in 1993. Current production levels in the United States point to it only being used in small-scale research.